Compare Vanguard Intermediate Term Corporate Bond ETF (VCIT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Intermediate Term Corporate Bond ETF vs Zoetis Inc — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $80.48, while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals.
| VCIT | ZTS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $84.82 | $150.61 |
52-Week Low | $80.31 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCIT trades at $80.46, down 0.09% on the day, with a bearish technical signal from moving averages but bullish oscillators. The ETF offers a 4.8% yield and low 0.03% expense ratio, attracting institutional interest as seen with HB Wealth Management increasing holdings by 242.9% in Q3 2026 (SEC filing, September 2026). Recent news highlights its competitive edge in intermediate-term corporate bonds.
The outlook remains favorable for income investors seeking yield with moderate risk, though bearish momentum and interest rate sensitivity pose near-term headwinds. Key opportunities include cost efficiency and diversification, while risks involve market volatility and economic shifts affecting corporate credit.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
